ZYNE Zynerba Pharmaceuticals, Inc.

7.30
+0  (0%)
Previous Close 7.30
Open 7.30
Price To book 1.86
Market Cap 67.15M
Shares 9,199,000
Volume 112,586
Short Ratio 5.08
Av. Daily Volume 201,943

SEC filingsSee all SEC filings

  1. 8-K - Current report 17514352
  2. 8-K - Current report 17500338
  3. 8-K - Current report 162052342
  4. 8-K - Current report 162001315
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161993809

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
ZYN001
Fibromyalgia
Phase 2 to be initiated 2H 2017.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2 trial initiation announced January 3, 2017. Data are due late 1H 2017.
ZYN002
Fragile X syndrome
Phase 2 initiated September 2016. Data are due 1H 2017.
ZYN002
Osteoarthritis
Phase 2 dosing commenced August 2016. Data are due 1H 2017.
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Donald Trump On Weed Legalization: What’s In Store For Marijuana Stocks?
  2. Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 9.5%
  3. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome
  5. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  6. Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome
  7. Expert: Lack Of Catalysts, Hurdles Could Spell Trouble For Marijuana Stocks
  8. The 2016 Election Was A Tipping Point For Marijuana Stocks
  9. Coverage initiated on Zynerba Pharma by Cantor Fitzgerald
  10. Viridian Experts Talk Recent Cannabis Industry Deals: M&A, Capital Raises And IPOs
  11. Zynerba Updates Analysts On Cannabidiol Treatment
  12. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  13. Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases
  14. Marapharm Ventures Starts Construction on its Las Vegas Property
  15. Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society
  16. Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society
  17. ZYNERBA PHARMACEUTICALS, INC. Financials
  18. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  19. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  20. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. 8-K - Current report 17514352
  2. 8-K - Current report 17500338
  3. 8-K - Current report 162052342
  4. 8-K - Current report 162001315
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161993809
  6. 8-K - Current report 161990380
  7. 8-K - Current report 161966265
  8. 8-K - Current report 161941842
  9. 8-K - Current report 161937978
  10. 8-K - Current report 161934057